PubRank

Javier Martinez-Picado

Author PubWeight™ 115.17‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A whole-genome association study of major determinants for host control of HIV-1. Science 2007 15.19
2 Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012 5.52
3 HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010 5.36
4 Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004 4.52
5 Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009 3.68
6 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
7 Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol 2012 2.03
8 Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009 1.88
9 Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. PLoS Biol 2012 1.79
10 Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 2011 1.73
11 Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006 1.72
12 Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol 2007 1.64
13 Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011 1.61
14 Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 2008 1.58
15 Copy number variation of KIR genes influences HIV-1 control. PLoS Biol 2011 1.44
16 Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2011 1.41
17 HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog 2010 1.34
18 Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog 2013 1.33
19 Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008 1.29
20 Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002 1.28
21 Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 2006 1.26
22 HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics. PLoS One 2012 1.21
23 Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011 1.21
24 A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife 2013 1.19
25 Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein. J Virol 2008 1.16
26 Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 2002 1.15
27 HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology 2008 1.14
28 Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol 2010 1.12
29 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009 1.11
30 Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006 1.07
31 A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet 2013 1.05
32 Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 2009 1.05
33 Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions. J Clin Microbiol 2004 1.04
34 The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 2010 1.04
35 HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS 2012 1.03
36 A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol 2003 1.02
37 Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 2004 0.99
38 Drug uptake transporters in antiretroviral therapy. Pharmacol Ther 2011 0.98
39 Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr Drug Targets Infect Disord 2003 0.98
40 Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol 2007 0.95
41 Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2007 0.95
42 Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure. Antimicrob Agents Chemother 2010 0.94
43 Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther 2008 0.92
44 Random T-cell receptor recruitment in human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells from genetically identical twins infected with the same HIV-1 strain. J Virol 2007 0.91
45 Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains. Chem Biol 2010 0.91
46 Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 2006 0.90
47 Capture of cell-derived microvesicles (exosomes and apoptotic bodies) by human plasmacytoid dendritic cells. J Leukoc Biol 2012 0.90
48 Modelling HIV-1 2-LTR dynamics following raltegravir intensification. J R Soc Interface 2013 0.90
49 HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. Clin Infect Dis 2005 0.89
50 Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014 0.88
51 Exosomes and retroviruses: the chicken or the egg? Cell Microbiol 2010 0.88
52 Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection. Am J Epidemiol 2011 0.87
53 Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J Biol Chem 2011 0.87
54 Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol 2005 0.87
55 HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation. J Immunol 2012 0.87
56 Optimal antiviral switching to minimize resistance risk in HIV therapy. PLoS One 2011 0.86
57 Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013 0.86
58 Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. AIDS 2014 0.86
59 Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells. Traffic 2011 0.85
60 Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003 0.85
61 Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. J Virol 2009 0.85
62 Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 2004 0.85
63 Actin-binding protein drebrin regulates HIV-1-triggered actin polymerization and viral infection. J Biol Chem 2013 0.83
64 The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology 2013 0.83
65 A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis 2011 0.83
66 Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. AIDS 2014 0.82
67 Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region. J Mol Biol 2008 0.82
68 Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002 0.81
69 Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antivir Ther 2004 0.80
70 Attacking the HIV reservoir from the immune and viral perspective. Curr HIV/AIDS Rep 2013 0.80
71 In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection. PLoS One 2012 0.80
72 Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance. AIDS Res Hum Retroviruses 2006 0.80
73 Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology 2012 0.79
74 3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir Ther 2006 0.79
75 The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression. J Acquir Immune Defic Syndr 2008 0.78
76 AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN. Antimicrob Agents Chemother 2007 0.78
77 Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. J Clin Microbiol 2012 0.78
78 Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions. AIDS Res Hum Retroviruses 2008 0.77
79 Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? AIDS 2015 0.77
80 New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. Molecules 2009 0.76
81 A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. J Antimicrob Chemother 2011 0.76
82 Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes. J Acquir Immune Defic Syndr 2011 0.76
83 Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine 2011 0.75